Literature DB >> 18571489

Vascular malformations as underlying cause of chronic thromboembolism and pulmonary hypertension.

Charlene E U Oduber1, Victor E A Gerdes, Chantal M A M van der Horst, Paul Bresser.   

Abstract

We report four patients with chronic thromboembolic pulmonary hypertension (CTEPH) presumably due to recurrent pulmonary embolism from low-flow vascular malformations, and give a review of the literature. Venous malformations, such as those observed in Klippel- Trenaunay syndrome (KTS) can be associated with hypercoagulability, thrombosis and recurrent pulmonary embolism and ultimately CTEPH. Since many physicians appear unfamiliar with these potential complications, patients may experience a delayed diagnosis of this progressive and potentially life-threatening CTEPH.

Entities:  

Mesh:

Year:  2008        PMID: 18571489     DOI: 10.1016/j.bjps.2007.12.062

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  9 in total

Review 1.  Venous malformation: update on aetiopathogenesis, diagnosis and management.

Authors:  A Dompmartin; M Vikkula; L M Boon
Journal:  Phlebology       Date:  2010-10       Impact factor: 1.740

2.  Characterization of thrombosis in patients with Proteus syndrome.

Authors:  Kim M Keppler-Noreuil; Jay N Lozier; Julie C Sapp; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2017-06-19       Impact factor: 2.802

3.  MRI phenotypes of localized intravascular coagulopathy in venous malformations.

Authors:  Kevin S H Koo; Christopher F Dowd; Erin F Mathes; Kristina W Rosbe; William Y Hoffman; Ilona J Frieden; Christopher P Hess
Journal:  Pediatr Radiol       Date:  2015-07-05

4.  Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.

Authors:  Elisa Boscolo; Nisha Limaye; Lan Huang; Kyu-Tae Kang; Julie Soblet; Melanie Uebelhoer; Antonella Mendola; Marjut Natynki; Emmanuel Seront; Sophie Dupont; Jennifer Hammer; Catherine Legrand; Carlo Brugnara; Lauri Eklund; Miikka Vikkula; Joyce Bischoff; Laurence M Boon
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

Review 5.  Venous Thromboembolism in Pediatric Vascular Anomalies.

Authors:  Taizo A Nakano; Chadi Zeinati
Journal:  Front Pediatr       Date:  2017-07-24       Impact factor: 3.418

6.  Pulmonary thromboendarterectomy in the setting of a mediastinal venous malformation with a congenitally absent left subclavian vein.

Authors:  Vickram Tejwani; Karunakaravel Karuppasamy; Marcelo P Gomes; Abraham Levitin; James M Luethke; Christopher J Morin; Nicholas G Smedira; Gustavo A Heresi; Wayne F Yakes
Journal:  Pulm Circ       Date:  2017-02-01       Impact factor: 3.017

7.  Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.

Authors:  Kim M Keppler-Noreuil; Jay Lozier; Neal Oden; Anjali Taneja; Jasmine Burton-Akright; Julie C Sapp; Leslie G Biesecker
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-09-06       Impact factor: 3.359

8.  Thrombotic Complications in Venous Malformations: Are There Differences Between Facial and Other Localizations?

Authors:  Simon Soudet; Stephanie Dakpe; Sandra Le Gloan; Esther Carmi; Jean Philippe Arnault; Sylvie Testelin; Marie-Christine Plancq; Bernard Devauchelle; Marie Antoinette Sevestre
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

9.  Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.

Authors:  Sandra D Castillo; Elena Tzouanacou; May Zaw-Thin; Inma M Berenjeno; Victoria E R Parker; Iñigo Chivite; Maria Milà-Guasch; Wayne Pearce; Isabelle Solomon; Ana Angulo-Urarte; Ana M Figueiredo; Robert E Dewhurst; Rachel G Knox; Graeme R Clark; Cheryl L Scudamore; Adam Badar; Tammy L Kalber; Julie Foster; Daniel J Stuckey; Anna L David; Wayne A Phillips; Mark F Lythgoe; Valerie Wilson; Robert K Semple; Neil J Sebire; Veronica A Kinsler; Mariona Graupera; Bart Vanhaesebroeck
Journal:  Sci Transl Med       Date:  2016-03-30       Impact factor: 17.956

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.